Success Story: EB1A Approved Despite RFE For a Postdoctoral Researcher From Italy, Thanks to Our Expert Guidance
Client’s Testimonial:
“I had a great experience with WeGreened. The team was highly efficient, responsive, and always available to address any concerns throughout my case. Their professionalism and dedication made the process much smoother, and I truly appreciate their support.”
On October 23rd, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Researcher in the Field of Pharmaceutical Nanotechnology (Approval Notice).
General Field: Pharmaceutical Nanotechnology
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: Italy
State of Residence at the Time of Filing: California
Approval Notice Date: October 23rd, 2025
Processing Time: 5 months, 18 days (Premium Processing Requested)
Case Summary:
Our client, a highly accomplished pharmaceutical nanotechnology specialist with a Ph.D. in chemical and pharmaceutical sciences, retained North America Immigration Law Group (Chen Immigration) to represent the case before USCIS. Despite receiving a Request for Evidence (RFE), our team successfully secured approval of the petition.
With advanced expertise encompassing drug delivery system development, tissue-engineered scaffold design, and physicochemical analysis of biopharmaceutical products, the client is recognized among a select group of leading professionals in the field. The client is particularly well-known for work on biodegradable electrospun scaffolds that support enhanced skin regeneration – an innovation with crucial applications in wound healing and regenerative medicine.
At North America Immigration Law Group, we applied our in-depth EB-1A case strategy to demonstrate both the national significance and the extraordinary merit of the client’s contributions. Multiple forms of evidence were presented to establish eligibility under the rigorous USCIS regulatory standards:
- A substantial and influential publication record, including 28 peer-reviewed journal articles (with 10 first- or co-first-authored) and 28 scientific abstracts (17 first-authored), reflecting strong leadership and productivity in pharmaceutical nanotechnology.
- High scientific influence, shown through 685 citations worldwide, is clear proof that the client’s research advances the work of many other experts and supports ongoing innovation in drug formulation and biotechnology.
- Trusted expertise as a reviewer, with at least 15 scientific peer-review evaluations, demonstrating that respected journals rely on the client’s professional judgment to assess new advances in the field.
- Research tied to major international funding initiatives, including programs supported by NextGenerationEU and Horizon 2020, indicating that the client’s work aligns with large-scale priorities in biomedical advancement and public health outcomes.
To further highlight the client’s respected standing, the case also included four persuasive recommendation letters from well-established experts in the field. Each recommender attested to the novelty, impact, and critical importance of the client’s discoveries:
“When considering these advantages, it is apparent that [Client’s] research also benefits the U.S. by positioning the nation as a worldwide leader in healthcare and scientific innovation.”
By addressing every criterion with clear, compelling documentation and by crafting a thorough and effective response to the RFE, our legal team successfully demonstrated that the client is among the small percentage of professionals who have risen to the very top of their field.
We are proud to share that the EB-1A I-140 petition has been approved, marking another successful outcome for our firm and another opportunity for a talented researcher to continue making important contributions in the United States biopharmaceutical industry.